Baseline myeloperoxidase levels effectively discriminated acute myocardial infarction from noncoronary chest pain (AUC 0.91; 95% CI 0.82-0.99; P<0.0001).
Observational
Does baseline myeloperoxidase (MPO) measurement improve the early diagnosis of acute myocardial infarction in patients admitted with chest pain?
Baseline levels of MPO, combined with CK-MB and Troponin I, provide high diagnostic accuracy for early detection of acute myocardial infarction in patients with chest pain.
Effect estimate: AUC 0.91 (95% CI 0.82-0.99)
p-value: p=< 0.0001
Myeloperoxidase (MPO) is an inflammatory marker, elevated in acute coronary syndromes (ACSs), especially in acute myocardial infarction (AMI) cases. This study aimed to evaluate the diagnostic power of MPO in AMI patients. MPO, creatine kinase (CK) MB, and Troponin I (cTn I) were performed for all study patients. Area under the curves (AUCs) and 95% confidence intervals (CI); P values of baseline levels of MPO for discriminating AMI patients from noncoronary chest pain (NCCP) patients, stable angina (SA) patients, and unstable angina (UA) patients were 0.91, 95% CI: 0.82-0.99; P < 0.0001, 0.87, 95% CI: 0.77-0.98; P < 0.0001, and 0.72, 95% CI: 0.58-0.85; P = 0.002, respectively. For diagnosing AMI from ACS patients, MPO was the most efficient marker than others markers with efficiency 82.5% within 0-6 hr after the onset time of chest pain. A predictive score that depends on a combination of baseline levels of three markers (MPO, CK-MB, and TnI) was correctly discriminated 91% of the AMI patients with high specificity 76%. In conclusion, the use of baseline levels of three biomarkers in combination could confer the information that is required for best available early diagnosis of AMI.
Omran et al. (Fri,) conducted a observational in Acute myocardial infarction. Baseline myeloperoxidase (MPO) levels vs. Noncoronary chest pain, stable angina, and unstable angina was evaluated on Discrimination of acute myocardial infarction from noncoronary chest pain (AUC 0.91, 95% CI 0.82-0.99, p=< 0.0001). Baseline myeloperoxidase levels effectively discriminated acute myocardial infarction from noncoronary chest pain (AUC 0.91; 95% CI 0.82-0.99; P<0.0001).